Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas

Trial Profile

Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Brain cancer; Glioblastoma; Glioma; Gliosarcoma
  • Focus Diagnostic use
  • Sponsors Medac
  • Most Recent Events

    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top